NCT04042753 2025-08-08
Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT03930771 2022-08-09
TMZ-Cap
Weill Medical College of Cornell University
Phase 2 Terminated
NCT04863339 2022-04-05
Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery
University of North Carolina, Chapel Hill
Phase 2 Withdrawn
NCT02749227 2021-04-27
PASSILCORT
Columbia University
Phase 2 Terminated
NCT04106843 2020-09-07
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00616642 2020-08-14
Rosiglitazone in Treating Patients With Pituitary Tumors
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT00601289 2020-07-31
Temozolomide in Treating Patients With Invasive Pituitary Tumors
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT00939523 2020-01-22
Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
Cedars-Sinai Medical Center
Phase 2 Completed
NCT01966809 2019-08-20
Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
Medical College of Wisconsin
Phase 2 Terminated
NCT00929669 2017-11-28
LAR
University of Pennsylvania
Phase 2 Terminated
NCT01849484 2016-08-01
HIPPO-SPARE 01
University of Erlangen-Nürnberg Medical School
Phase 2 Unknown